The Role of Beta-Blockers in the Treatment of Hypertension.
CONCLUSIONS AND RELEVANCE: Primary/essential hypertension in younger/middle-age is underpinned by high sympathetic nerve activity. In this age-group high resting heart rates and high plasma norepinephrine levels (independent of blood pressure) are linked to premature cardiovascular events and death. Thus, anti-hypertensive agents that increase sympathetic nerve activity ie diuretics, dihydropyridine calcium blockers, and ARBs, are inappropriate first-line choices in this younger age-group. Beta-blockers perform well vs randomised placebo and other antihypertensive agents regarding reduced risk of death/stroke/myocardial infarction in younger (<60 years) hypertensive subjects, and are a reasonable first-line choice of therapy (certainly in men). These facts should be reflected in the recommendations of guideline committees around the world.
PMID: 27957711 [PubMed - as supplied by publisher]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
More News: Atenolol | Beta-Blockers | Biology | Calcium | Cancer | Cancer & Oncology | Captopril | Cardiology | Cardiovascular | Coronary Heart Disease | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Heart Attack | Heart Disease | Hypertension | Obesity | Reflex Sympathetic Dystrophy | Research | Smokers | Stroke | Study